Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 3, 2019updated 25 Nov 2021 10:38am

Idorsia Pharmaceuticals selects Arkivum to preserve clinical data

Switzerland-based Idorsia Pharmaceuticals has selected Arkivum to protect and digitally store its clinical trial and research data.

Switzerland-based Idorsia Pharmaceuticals has selected Arkivum to protect and digitally store its clinical trial and research data.

Idorsia, which is born out of an Actelion de-merger, selected Arkivum’s e-archives platform to store its data, as well as to offer secure access for future use.

The data that needs to be stored includes previous Actelion data, information relating to inherited products returning from CROs and service providers, and the data the company itself generates.

Idorsia had received data from its CROs relating to the products from Actelion and the company needed to store the data for an extended period.

“Arkivum have impressed us with their flexibility and expertise and have proved a good vendor to work with.”

Idorsia Clinical and Regulatory Records manager Simon Souster said: “We were looking for the confidence that in 20/30/50 years’ time we can provide evidence if an auditor comes in and asks to see all documentation relating to a specific product or clinical trial, proving the integrity, chain of custody and the audit trail of our data”

Arkivum will work with Idorsia to outline their data processes and structures to aid in the long-term management of their data.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Simon added: “There are not many pharma companies that have an e-archive, and because of that there aren’t many supplier companies that have the GxP knowledge or understanding of the compliance requirements we need to adhere to, such as CFR 21.”

“Arkivum have impressed us with their flexibility and expertise and have proved a good vendor to work with as we look to build our archiving processes”.

In 2017, Idorsia reported positive results from a Phase II programme of ACT-541468 to treat patients with insomnia.

ACT-541468 is a dual orexin receptor antagonist (DORA) designed to target the orexin system to maintain natural sleep pattern.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU